Tag: Financing

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).

Issy-les-Moulineaux, July 1, 2025 (7am)
Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY)

Combined Company Expected to be Listed on NASDAQ Global Market

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or the “Company”) is pleased to announce it has entered into an agreement with Mill Road Capital II, L.P. (“Mill Road”) to purchase from Mill Road the outstanding share purchase warrant entitling Mill Road to acquire up to 2,250,000 common shares of Swiss Water. The share purchase warrant has an exercise price of $3.33 per share and expires on April 30, 2026. The purchase price for the share purchase warrant is $675,000. Completion of the purchase is anticipated to be July 3, 2025.

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today.

Strengthens Financial Position with Expanded Credit Facility and Flexibility for Future Strategic Equity Sales

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today the pricing of an underwritten public offering of $85 million aggregate principal amount of its 9.875% senior notes due 2030 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $12.75 million aggregate principal amount of the Notes to cover over-allotments. The offering is expected to close on July 8, 2025, subject to the satisfaction of customary closing conditions.